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Water channelAquaporins are protein channels that facilitate the ﬂow of water across plasma cell membranes in response to
osmotic gradients. This review summarizes the evidence that aquaporins play key roles in tumor biology includ-
ing tumor-associated edema, tumor cell migration, tumor proliferation and tumor angiogenesis. Aquaporin in-
hibitors may thus be a novel class of anti-tumor agents. However, attempts to produce small molecule
aquaporin inhibitors have been largely unsuccessful. Recently, monoclonal human IgG antibodies against extra-
cellular aquaporin-4 domains have become available and could be engineered to kill aquaporin-4 over-
expressing cells in the malignant brain tumor glioblastoma. We conclude this review by discussing future
directions in aquaporin tumor research. This article is part of a Special Issue entitled: Membrane channels and
transporters in cancers.
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Aquaporins (AQPs) are a family ofwater channel proteins, which are
found in the plasma cell membranes of various cells [1]. There are 14
AQPs inmammals, at least eight of which have been shown to transport
water. AQP3, AQP7 and AQP9 also transport glycerol and are termed
aquaglyceroporins [2]. Though some AQPs transport gases and ions inne channels and transporters inartiﬁcial systems, gas and ion transport are probably not relevant
under physiological conditions [3,4]. To date, the key function of AQPs
remains water transport.
AQPs assemble in cell membranes as homo-tetramers [5]. Each
monomer is about 30 kDa and has its own water pore. In general,
AQPs increase the water permeability of the plasma cell membrane
5–20 fold. AQP0 and AQP4 have unique properties; their tetramers as-
semble into higher order structures that form orthogonal arrays of par-
ticles. AQP4 exists as two isoforms, termed M1-AQP4 and M23-AQP4;
M1 is the full-length protein with the sequence starting at methionine
1, whereas M23 lacks the ﬁrst 22 amino acid sequence and starts at
methionine 23. M23-AQP4 assembles in large orthogonal arrays, but
Table 1
AQP expression in human tumors.
Tumor type Aquaporins AQP level References
Astrocytoma AQP1, 4, ?8, 9 high [21–32]
Breast cancer AQP5 high [77–79]
AQP1 high [79]
AQP4 low [79]
Cholangiocarcinoma AQP1 low [80]
AQP1 high [81]
Colorectal cancer AQP1, 3, 5 high [60,82–85]
AQP8 low [85,86]
Cervical cancer AQP1, 3 high [87]
AQP5 high [88]
Choroid plexus tumor AQP1 high [89]
Hemangioblastoma AQP1 high [90]
Laryngeal cancer AQP1 high [91]
Leukaemia AQP5 high (CML) [92]
Liver cancer AQP3, 5 high [93]
AQP8, 9 low [94]
Lung cancer AQP1, 3, 5 high [64,95,96]
AQP1, 4 high [97]
Meningioma AQP4 high [98,99]
Nasopharyngeal cancer AQP1 high [100]
Oesophageal cancer AQP3, 5 high [101,102]
Ovarian cancer AQP1, 5, 9 high [103,104]
Renal AQP3 high [105]
Skin, SCC AQP3 high [106]
Stomach cancer AQP5 high [107]
AQP4 low [108]
AQP3 high [109]
Thyroid cancer AQP4 high (papillary) [110]
AQP3, 4 low (undifferentiated) [110]
AQP7 high [111]
Tongue cancer AQP3, 5 high (SCC) [112]
Urinary bladder AQP3 low [113,114]
CML, chronic myelogenous leujaemia; SCC, squamous cell carcinoma; AQP level indicates
level of AQP expression in the tumor compared with the normal tissue.
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with M23 to form orthogonal arrays, the size of which increases with
increasing M23:M1 ratio [6]. Though in vitro studies show that AQPs
freely diffuse in the plasma cell membrane, in vivo AQPs may be
anchored to parts of the plasma cell membrane [7,8]. For example, in
the central nervous system AQP4 is concentrated in perivascular astro-
cyte endfeet [9]. Intracellular membrane proteins such as alpha
syntrophin [10] and extracellular matrix proteins such as agrin may
form part of the AQP4 anchoring mechanism [11], but further research
is required to deﬁne the molecular anchor.
In this review we discuss the functions of AQPs in tumor cells and




AQPs are widely distributed in human tissues and are generally pre-
served in mammals including rodents and humans [1]. In some organs,
such as the kidney, several AQPs are expressed and play a major role in
normal function [1,12]. For example, in response to antidiuretic hor-
mone (vasopressin), AQP2 (which is found in intracellular vesicles) be-
comes expressed in the apical plasma cell membrane of collecting duct
epithelial cells and increases the reabsorption of urine by the kidney.
Humans with AQP2 mutations have congenital nephrogenic non-X-
linked diabetes insipidus thus conﬁrming the key role of AQP2 in
water reabsorption by the kidney. In other organs, such as the brain,
AQPs do not appear to play amajor role in normal function, but become
important in pathological conditions [1]. In mice that lack AQP4, which
is normally expressed in perivascular astrocyte foot processes, the brain
is phenotypically normal at baseline. In cerebral ischemia, brain tumors,
bacterialmeningitis and other conditions AQP4 becomes upregulated in
astrocytes and facilitates brain edema formation and elimination. Re-
cently, however, AQP4 was proposed to play a role in the clearance of
solutes from the interstitialﬂuid of normal brain through a paravascular
pathway termed the glymphatic system [13]. In some locations, such as
the stomach, AQPs do not seem to be important for normal functions
or in pathological conditions. Although AQP4 is expressed in the
basolateral plasma cell membrane of gastric parietal cells, which are re-
sponsible for secreting hydrochloric acid, AQP4 deletion in mice does
not affect gastric acid secretion. Aquaglyceroporins are involved in cel-
lular metabolism [1,2]. AQP3 is expressed in the stratum corneum
layer of the skin. AQP3 deletion in mice impairs skin hydration, elastic-
ity, barrier recovery and wound healing due to lack of glycerol in the
cells. These deﬁciencies in AQP3 null mice can be reversed by glycerol
administration. AQP7, expressed in adipocytes, controls glycerol move-
ment into and out of the cell [1]. AQP7 deletion in mice is associated
with adipocyte hypertrophy, likely due to impaired glycerol exit from
the adipocytes.
Several studies report regulation of AQP expression [1]. Though
AQPs become upregulated or downregulated in response to different
pathologies, it is impossible to determine from these descriptive studies
the roles of AQP in these pathological conditions.
2.2. Tumors
Several authors have suggested a role for AQPs in cancer [14–20].
Table 1 summarizes AQP expression in different tumors. In general,
tumor cells overexpress AQPs including AQPs that are normally found
in their cell of origin as well as AQPs not present in the originating
cell. In tumor cells, AQPs are expressed in the plasma cell membrane
as well as the cytoplasm. There is often a strong correlation between
the level of AQP expression and tumor grade. An example is diffuse as-
trocytoma, which is an inﬁltrating brain tumor that arises from astro-
cytes. Diffuse astrocytomas are histologically classiﬁed as grades II, IIIor IV,with themostmalignant grade IV also termed glioblastoma. Astro-
cytes normally express AQP4 in their perivascular foot processes. Nor-
mal astrocytes express AQP4, but little or no AQP1 and AQP9. We
initially reported, using immunohistochemistry, strong AQP4 [21] and
AQP1 [22] expression in diffuse astrocytomas with the level of expres-
sion positively correlating with tumor grade. There is now substantial
evidence from different investigators that AQP1, AQP4 and AQP9 are
strongly expressed in human astrocytomas [21–33]. Another example
of human tumors that strongly express AQPs is epithelial ovarian tu-
mors. By immunoblot there is substantially higher AQP7 and AQP9 pro-
tein expression in malignant and borderline tumors compared with
benign tumors and normal ovarian tissue with AQP9 expression level
positively correlating with tumor grade [34]. Though some tumor
types show reduced AQP expression compared with their cell of origin,
this is only seen for individual AQPs; when considering several AQPs,
there appears to be increased overall AQP expression in all tumors listed
in Table 1. In some cases there is correlation between increased AQP ex-
pression in the tumor and patient prognosis. Potential caveats of these
studies include reporting bias for positive studies, failure to distinguish
tumor cells from other cell types found within the tumor (e.g. reactive
astrocytes, ﬁbroblasts or leukocytes) and the poor speciﬁcity of some
antibodies used for immunostaining e.g. anti-AQP9. Notwithstanding
these caveats, the large number of tumor AQP expression studies raises
the intriguing hypothesis that AQPs contribute to carcinogenesis in a
range of tumor types.
3. AQP functions
In addition to thewell-established role of AQPs inmaintaining tissue
water balance, other roles of AQPs include facilitating cellmigration, cell
proliferation and cell adhesion (Fig. 1). Under each section below, we
ﬁrst discuss the role of AQPs in normal cells, followed by their role in
tumor cells. The functional data discussed here are largely derived
Fig. 1.Roles of AQPs in cancer. A. Cellmigration. AQP polarizes to the leading end of the cell and facilitates formation of the lamellipodium. B. Cell proliferation. Aquaglyceroporin facilitates
glycerol entry into the cell, which is essential for biosynthesis. AQPmaydirectly interactwith oncogenes. C. Cell adhesion. AQP0–AQP0 or AQP4–AQP4 binding increases cell–cell adhesion.
AQPmay increase adhesion of the cell to the extracellular matrix. D. Tissue water balance. Example of brain where AQP4 controls water ﬂow between the brain and major ﬂuid compart-
ments: 1) glia limitans (brain–subarachnoid cerebrospinal ﬂuid), 2) ependyma (brain–ventricular cerebrospinal ﬂuid), 3) astrocyte foot processes (brain–blood). A, astrocyte; csf, cere-
brospinal ﬂuid; V, ventricle.
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interpreted with caution because of compensatory effects that may
have developed in these mice as a result of longstanding AQP deletion.
To minimize compensatory effects, some authors have created central
nervous system speciﬁc AQP4 deletion inmice [35]. Ideally, conditional-
ly inducible AQP knockoutmice are required to eliminate the confound-
ing effect of long-term adaptation to AQP deletion. Such mice are not
currently available, but may provide more deﬁnitive information
about AQP4 function. Another way to elucidate AQP function is to inhib-
it AQPs; this is not currently possible because of a lack of non-toxic, spe-
ciﬁc AQP inhibitors [36].
3.1. Tissue water balance
There is now substantial evidence that AQPs play a major role in
maintaining water balance in several tissues. One of the ﬁrst organs to
be investigated following the discovery of AQPs was the kidney, in
which multiple AQPs (AQP1, AQP2, AQP3 and AQP4) are responsible
for water absorption and elimination [12]. Key roles for AQPs have
also been deﬁned in the central nervous system, with AQP4 playing a
central role in edema ﬂuid accumulation and elimination, and AQP1 in
cerebrospinal ﬂuid production [37]. The mechanisms of AQP4 involve-
ment in brain edema are discussed in detail elsewhere [37]. In the sali-
vary gland, AQP5 is found in the apical plasma cell membrane of acinar
epithelial cells and plays a role in osmotic water transport across the
cells into the sweat duct [38]. In some tissues, loss of AQP expression
in mice does not inﬂuence function, e.g. deletion of AQP1, AQP3,
AQP4, and AQP5 inmouse lacrimal glands does not affect tear secretion,
probably due to the low level of transepithelial water transport rates in
these tissues [39]. In general, AQPs facilitate water ﬂow across cells in
response to osmotic gradients produced by salt transport.
A major role for aquaporins in tumor edema was ﬁrst postulated by
Saadoun et al. who showed that astrocytomas express high levels of
AQP1 [22] and AQP4 [21] with the level of AQP expression positively
correlating with the presence of brain tumor edema on computed to-
mography. The most malignant astrocytomas also express AQP9 [23,
28,29]. AQP4 is expressed by astrocytoma cells, but also by reactive as-
trocytes in and around the tumor [21]. Subsequent experiments showed
that AQP4 deletion in mice increases edema around B16F10 brainmelanoma [40]. In this mouse model there is prominent reactive gliosis
around the melanoma. These ﬁndings suggest that the increased AQP4
expression by reactive astrocytes in and around the tumor facilitate
elimination of brain edema ﬂuid. Whether AQP4 expressed in tumor
cells also plays a role in brain edema remains unknown and could be de-
ﬁned by implanting AQP4-expressing and non-expressing tumor cells
in mice and quantifying the water content of the tumor and brain. Be-
cause the brain is surrounded by the non-distensible skull, brain
tumor edema is amajor clinical problem that causes increased intracra-
nial pressure, brain ischemia, herniation and, ultimately, brain death. To
date, a role for AQPs in tissue edema associatedwith tumors outside the
central nervous system has not been investigated.
3.2. Cell migration
An unanticipated role for AQPs in facilitating cell migration was ﬁrst
suggested by Loitto et al. who studied AQP9 in neutrophils [41]. Subse-
quently, Saadoun et al. showed that several AQPs facilitate cell migration
in different cell types including AQP1 in aortic endothelial cells [42] and
AQP4 in astrocytes [43]. The overall conclusion from several studies
in vitro and in vivo is that AQP expression enhances cell migration to-
wards a chemotactic stimulus [41–47]. The exact mechanism remains
unclear, but may involve targeted water entry into the leading edge of
a migrating cell, which enhances formation of the lamellipodium (a ﬂat-
tened protrusion at the leading end of amigrating cell, which is essential
for cell motility) [48]. The idea that AQPs facilitate formation of the
lamellipodium is consistent with the polarization of AQPs to the leading
end of migrating cells. It has been suggested that AQPs also facilitate the
rapid changes in cell shape that take place as a migrating cell squeezes
through the tortuous extracellular space [14]. Such changes in cell vol-
ume are likely to require rapid ﬂow of water into and out of the cell.
Some authors have recently suggested that cells may utilize directed
water permeation mediated by AQPs to create a net inﬂow of water
and ions at the cell leading edge and a net outﬂow of water and ions at
the trailing edge leading to net cell displacement [49]. This mechanism,
termed the osmotic engine model, may allow cell migration through
conﬁnedmicro-spaces without the need for actin depolymerization–po-
lymerization or myosin II-mediated contractility. It is important to note
that lack of AQPs does not entirely inhibit cell migration, but renders
Fig. 2. Proposed role of AQP in increasing directionality of migrating cell. A. AQP polarizes
to the leading end of the cell thus ensuring that the lamellipodium forms in the direction of
the chemotactic gradient. The cell migrates toward the chemotactic gradient. B. Without
AQP, the lamellipodium does not form in the direction of the chemotactic gradient and,
therefore, the cell migrates in a more tortuous route.
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whyAQP-nullmice develop normally in utero even though cellmigration
is an important component of embryogenesis.
Tumor cell migration is a fundamental property of different cancers
and contributes to tumor cell inﬁltration into surrounding tissue as well
as themetastatic spread. B16F10melanoma cells and 4T1 breast cancer
cells transfected to express AQP1 were more likely to extravasate after
tail vein injection inmice [50]. The resulting lung tumorsweremore dif-
fusely inﬁltrating into the surrounding alveolar tissue compared with
tumor cells lacking AQP1. AQP1 is important for endothelial cell migra-
tion that takes place during angiogenesis, which is vital to permit solid
tumors to grow rapidly. Melanoma tumors produced by subcutaneous
implantation of B16F10 cells grow faster in wildtype than AQP1 null
mice [42]. Histological examination of these tumors revealed that
AQP1 deﬁciency is associated with impaired tumor angiogenesis.
Tumor vascular endothelial cells express AQP1, which plays a major
role in tumor angiogenesis by facilitating endothelial cell migration.
These ﬁndings are supported by several follow-on studies. One study
found reduced proliferation of implanted melanoma cells in mice treat-
ed with AQP1 siRNA [51]. AQP1 deﬁciency in mice that spontaneously
develop well-differentiated breast adenomas with lung metastases re-
duced total tumor mass and volume compared with wildtype mice,
due to impaired angiogenesis in the AQP null mice [52]. A key role for
AQP1 in enhancing angiogenesis has also been shown in several other
non-tumor pathologies including liver cirrhosis [53,54] and hypoxia-
inducible angiogenesis in the retina [55]. Together, these ﬁndings sug-
gest that, by enhancing cell migration and angiogenesis, AQPsmay facil-
itate tumor growth, local inﬁltration and metastasis.
Further work is required to deﬁne the role of AQPs in tumor cell
inﬁltration. This could be achieved by mapping the location of AQP-
expressing and non-expressing astrocytoma cells in human tumor spec-
imens. If AQP expression increases tumor cell inﬁltration, then we hy-
pothesize that the AQP-expressing cells will be located in inﬁltrative
parts of the tumor whereas non-AQP expressing cells that should be
mostly within the tumor core. A recent study reported AQP1 expression
in astrocytoma cells in areas of tumor inﬁltration, distant from the ne-
crotic tumor core, thus supporting this hypothesis [25]. Experiments
are also required to investigate whether it is the water transport, or an-
other, unknown AQP function that contributes to tumor cell inﬁltration
and spread.
The mechanism by which AQPs facilitate cell migration remains un-
known. Here we propose a novel hypothesis, that AQPs do not increase
the speed of migrating cells, but by polarizing to the leading edge, AQPs
ensure that the lamellipodium forms in the direction of the chemotactic
gradient. This effect may enhance the directionality of migration i.e.
cells expressing AQPs follow a less tortuous route towards their target
compared with cells lacking AQPs (Fig. 2). A detailed description of
the molecular basis of cell migration is beyond the scope of this paper
and is the subject of other reviews [56,57]. A useful analogy for amigrat-
ing cell is amoving car. Thewheels of the car are the integrins,which are
transmembrane proteins that allow cell–cell and cell–extracellular ma-
trix interaction during cell migration. The petrol in the car is the ATP
that provides the energy for cell migration. The car engine is the actin
cytoskeleton that forms the propulsion system for cell migration. The
road is the extracellular space. A map is also needed, which is provided
by several proteins that facilitate detection of the chemotactic gradient.
Here we propose that the AQPs are the steering wheel, which ensures
that the moving car heads towards its destination. Further experiments
are required to test these ideas, by determining the effect of AQP expres-
sion on the speed, directionality and tortuosity of cells inmigrating che-
motactic chambers.
3.3. Cell proliferation
AQP3, which is expressed in the epidermis, enhances the prolifera-
tion rate of basal keratinocytes [46]. AQP3 null mice have impairedwound healing, due to reduced glycerol and ATP content in the
keratinocytes, which are required for biosynthesis [58,59]. Little is
known about the role of aquaglyceroporins 7 and 9 in the proliferation
of normal cells.
There is direct and indirect evidence that AQP3 and AQP5 play a role
in tumor cell proliferation. AQP5might interact with the Ras pathway in
colon cancer [60]. Ras activation switches on other proteins that ulti-
mately turn on genes involved in cell growth, differentiation and surviv-
al. Another study showed AQP5-facilitated lung cancer cell proliferation
and migration, possibly through activation of the EGFR/ERK/p38 MAPK
signaling pathway [61]. These AQP5–oncogene interactions may repre-
sent novel AQP functions, which are unrelated to water transport. AQP3
null mice are remarkably resistant to the development of skin tumors
following exposure to the tumor initiator and promoter, phorbol ester
[62]. Glycerol supplementation corrected the reduced proliferation in
AQP3 deﬁciency, with cellular glycerol, ATP, and proliferative ability
being closely correlated. There is, therefore, an established link between
AQP3 expression in the epidermis and skin cancer. It is worth noting
here that some moisturizing creams (such as Eucerin®, Be+®,
HydrAction®) are marketed to improve skin hydration by increasing
AQP3 expression in keratinocytes. At least one investigator has cau-
tioned the cosmetics industry that products that increase AQP3 expres-
sion in the skin might be carcinogenic [63]. AQP3 expression is high in
non-small cell lung cancer [64] and, in a mouse model, AQP3 knock-
down suppressed tumor growth and reduced angiogenesis in human
non-small cell lung cancer xenografts [65].
Though a role for some AQPs in facilitating tumor cell proliferation
seems likely, further studies are required to deﬁne the link between
the expression level of some AQPs, notably AQP3 and AQP5, and
tumor cell proliferation. This could be achieved in a variety of human tu-
mors by doubly immunostaining for theAQPof interest and the cell pro-
liferation marker Ki67. If AQP increases cell proliferation, then a greater
proportion of AQP+ than AQP− tumor cells should also be Ki67+. It is
unclear whether and how some AQPs directly interact with oncogenes
or whether the increased proliferation in AQP expressing tumor cells
is a secondary effect of increasing the glycerol content in the cell. It is
also unclear whether the water transporting function of AQPs is neces-
sary to increase cell proliferation.
Fig. 3. AQP4-IgG linked to toxin as a potential treatment for glioblastoma. A. AQP4-IgG
binds AQP4 on astrocyte foot processes and is not internalized. Toxin remains linked to
AQP4-IgG. B. AQP4-IgG binds AQP4 on glioblastoma cell and becomes internalized.
Toxin is released from AQP4-IgG and kills the cell.
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A role for AQP0 in cell–cell adhesion is well established. AQP0 is
expressed in lens ﬁber cells in the eye where it constitutes about 50%
of the ﬁber cell membrane protein. Studies using AQP0 null mice re-
vealed that AQP0 is important for maintaining the structure of
interlocking protrusions that is critical to the integrity and transparency
of the lens. A role for AQP4 in cell–cell adhesion was also proposed
based on structural considerations [66]. AQP4 contains a short helix in
an extracellular loop, which mediates weak interactions between
AQP4 molecules in adjoining plasma cell membranes, in effect binding
adjacent cells to each other. Expression of AQP4 in L-cells (which lack
endogenous adhesion molecules) resulted in clustering of the cells
thus supporting the idea that AQP4may play a role in cell–cell adhesion.
There is also evidence against a signiﬁcant effect of AQP4 expression on
adhesion in several different cell types, including L-cells [67]. Recent ex-
periments show that during cell migration, M1-AQP4 isoforms (which
exist as individual tetramers) polarize to the leading edge of the cell,
to support cell migration [68]. However, the larger M23-AQP4 rich or-
thogonal arrays do not enter the lamellipodium, but become bound
with adhesion complexes, suggesting a role for M23-AQP4 but not
M1-AQP4 in cell adhesion to the extracellular matrix. We conclude
that data regarding the role of AQP4 in cell adhesion are contradictory.
It is thus unclear whether AQP4 plays any role in tumor cell adhesion.
4. AQP-based tumor therapeutics
If AQPs play a role in tumor cell inﬁltration, metastasis, proliferation
and possibly cell adhesion, then AQP modulators may be useful anti-
cancer agents. For effects that are dependent on the water transport
property of AQPs such as tumor cell migration, inhibitors of AQP trans-
port are required. For other effects that are independent of water trans-
port through the AQP channel other drugs are required, e.g. disruptors
of AQP-oncogene interaction to reduce cell proliferation.
To illustrate the therapeutic potential of AQP inhibitors, we consider
glioblastoma, which is the most common primary brain tumor with
fatal prognosis. The median survival from diagnosis is about a year
evenwith aggressive treatment (radical surgery, radiotherapy and tem-
ozolomide chemotherapy) [69,70].Whatmakes glioblastoma so aggres-
sive is its ability to inﬁltrate extensively into the brain, which renders
the tumor impossible to excise surgically. Drugs that inhibit water
ﬂow through the AQP4 pore may reduce tumor cell inﬁltration thus
converting a tumor that is not surgically excisable into a tumor with
well-deﬁnedmargins that can be surgically resected. Currently, chemo-
therapy and radiotherapy target the rapidly dividing cells. By eliminat-
ing the most inﬁltrative cells, AQP4 inhibitors would offer a novel
therapeutic option, which targets the main cause of tumor malignancy
in glioblastoma. Vascular endothelial cells within glioblastoma express
AQP1 and, therefore, AQP1 inhibitors may reduce angiogenesis, which
would secondarily inhibit glioblastoma growth.
A recent review has summarized attempts to develop AQP-based
therapeutics and concluded that such attempts have been largely un-
successful [36]. Heavy metals such as mercury inhibit AQP1 but are
too toxic for clinical use. There are several reports of AQP4 inhibitors in-
cluding acetazolamide, anti-epileptic drugs, bumetanide, sumatriptan
and thiadiazole [71–73]. Unfortunately, follow-on studies on these com-
pounds by other investigators using different assays have failed to con-
ﬁrm AQP4 inhibition. For a detailed discussion on the issues related to
discoveringAQP inhibitors please refer to the recent reviewbyVerkman
et al. [36]. One interesting development is the discovery of an autoanti-
body against AQP4 found in patients with an inﬂammatory demyelinat-
ing disease of the central nervous system termed neuromyelitis optica,
termed AQP4-IgG or NMO-IgG [74]. AQP4-IgG is pathogenic, by binding
AQP4 on astrocytes and causing complement-dependent astrocyte
damage, followed by leukocyte inﬁltration into the lesion. Monoclonal
AQP4-IgG can now be produced artiﬁcially [75]. AQP4-IgG linked to atoxin could be used for destroying AQP4-expressing glioblastoma
cells, most of which express large amounts of AQP4. However, it is un-
clear whether eliminating the AQP4-expressing subpopulation of
tumor cells will render the glioblastoma less aggressive. Local AQP4-
IgG delivery in human glioblastoma is possible by using wafers posi-
tioned against the resection cavity wall or by convection-enhanced de-
livery. The side effect of AQP4-IgG treatment may be neuromyelitis
optica type symptoms caused by AQP4-IgG-mediated damage to nor-
mal astrocytes. A more elegant approach is to link AQP4-IgG to a toxin
that becomes activated when AQP4-IgG is internalized (Fig. 3). There
is evidence that intact astrocytes (which express AQP4 in the
perivascular foot processes) do not internalize AQP4-IgG, but cells that
express AQP4 throughout the plasma cell membrane (such as glioblas-
toma) internalize AQP4-IgG [76]. This observation suggests that, com-
pared with normal astrocytes, AQP4-expressing glioblastoma cells
may be selectively vulnerable to damage by AQP4-IgG internalization,
thus reducing the side effects of this treatment.5. Future directions
Several roles of AQPs in tumor biology are beginning to emerge.
There is a need to deﬁne further themolecularmechanisms responsible
for AQP-mediated cell migration and cell proliferation. It is unclear
whether the water transporting property of AQPs is important or
whether there are as yet unidentiﬁed interactions between AQPs and
oncogenes. Further research is also required to discover non-toxic AQP
inhibitors, which can be used to deﬁne AQP functions and as novel can-
cer therapeutics. AQP inhibitors, which could target tumor inﬁltration,
metastasis and angiogenesis, might be used in combination with cur-
rent cancer therapeutics that target the proliferating tumor cells.
2581M.C. Papadopoulos, S. Saadoun / Biochimica et Biophysica Acta 1848 (2015) 2576–25836. Conclusion
Over the last few years there emerged a surprising link between
AQPs and cancer. AQPs appear to play a key role in several tumor-
related processes including tumor edema, tumor cell migration, tumor
proliferation and angiogenesis. AQP inhibitors may thus be useful anti-
cancer drugs. Unfortunately, no such inhibitors are available to date.
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